54013-18-2

Basic information

• Product Name: 5-chloro-2-(1H-tetrazol-5-yl)aniline
• Synonyms: 5-chloro-2-(1H-tetrazol-5-yl)aniline;5-Chloro-2-(1H-tetrazol-5-yl)benzenamine;Einecs 258-923-1;BenzenaMine, 5-chloro-2-(2H-tetrazol-5-yl)-;5-Chloro-2-(1H-tetrazol-5-yl)aniline 97%;5-Chloro-2-(1H-tetrazol-5-yl)aniline97%
• CAS NO: 54013-18-2
• Molecular Formula: C₇H₆ClN₅
• Molecular Weight: 195.60904
• EINECS: 258-923-1
• Mol File: 54013-18-2.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 436.5 °C at 760 mmHg
• Flash Point: 217.8 °C
• Appearance: /
• Density: 1.540
• Vapor Pressure: 8.02E-08mmHg at 25°C
• Refractive Index: 1.692
• PKA: 4.37±0.10(Predicted)
• CAS DataBase Reference: 5-chloro-2-(1H-tetrazol-5-yl)aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 5-chloro-2-(1H-tetrazol-5-yl)aniline(54013-18-2)
• EPA Substance Registry System: 5-chloro-2-(1H-tetrazol-5-yl)aniline(54013-18-2)

Safety Data

• Hazardous Substances Data: 54013-18-2(Hazardous Substances Data)

Usage

General Description

5-chloro-2-(1H-tetrazol-5-yl)aniline is a chemical compound with the molecular formula C7H6ClN5. It is a chlorinated aniline derivative with a tetrazole ring substitution. 5-chloro-2-(1H-tetrazol-5-yl)aniline has potential applications in the pharmaceutical industry as a building block for the synthesis of various drugs and pharmaceuticals. The presence of both the chloro and tetrazole moieties in its structure make it useful for pharmaceutical research and development. Additionally, it has been studied for its potential biological activities, including antiviral and antimicrobial properties. However, due to its chemical properties and potential biological activities, caution should be exercised in handling and using this compound in laboratory and industrial settings.

InChI:InChI=1/C7H6ClN5/c8-4-1-2-5(6(9)3-4)7-10-12-13-11-7/h1-3H,9H2,(H,10,11,12,13)

Upstream product

• 92567-02-7 C₇H₄ClN₅O₂ 
• 34662-32-3 4-chloro-2-nitrobenzonitrile 
• 38487-86-4 2-amino-4-chlorobenzonitrile 

Downstream Products

• 1083418-33-0 1-(4-bromo-benzyl)-5-methyl-1H-[1,2,3]triazole-4-carboxylic acid [5-chloro-2-(1H-tetrazol-5-yl)-phenyl]-amide 
• 1083418-96-5 5-(cyclopentanecarbonyl-amino)-3-methyl-thiophene-2-carboxylic acid [5-chloro-2-(1H-tetrazol-5-yl)-phenyl]-amide 
• 1083418-75-0 4-methyl-2-morpholin-4-yl-thiazole-5-carboxylic acid [5-chloro-2-(1H-tetrazol-5-yl)-phenyl]-amide 
• 1083418-45-4 4-methyl-2-(4-trifluoromethyl-phenyl)-thiazole-5-carboxylic acid [5-chloro-2-(1H-tetrazol-5-yl)-phenyl]-amide 
• 1083418-31-8 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [5-chloro-2-(1H-tetrazol-5-yl)-phenyl]-amide 
• 1083418-29-4 5-(4-chloro-phenyl)-trifluoromethyl-furan-3-carboxylic acid [5-chloro-2-(1H-tetrazol-5-yl)-phenyl]-amide 
• 1083418-51-2 5-(4-chloro-phenyl)-2-methyl-furan-3-carboxylic acid [5-chloro-2-(1H-tetrazol-5-yl)-phenyl]-amide 
• 1083418-57-8 5-methyl-2-phenyl-2H-[1,2,3]triazole-4-carboxylic acid [5-chloro-2-(1H-tetrazol-5-yl)-phenyl]-amide 
• 1083418-92-1 4-methyl-2-pyridin-4-yl-thiazole-5-carboxylic acid [5-chloro-2-(1H-tetrazol-5-yl)-phenyl]-amide 
• 1080029-22-6 N-[5-chloro-2-(1H-tetrazol-5-yl)-phenyl]-3-(4-chloro-3-trifluoromethyl-phenyl)-3-oxo-propionamide 
• 1034331-74-2 6-bromo-2-oxo-2H-chromene-3-carboxylic acid [5-chloro-2-(1H-tetrazol-5-yl)-phenyl]-amide 
• 1034331-04-8 (E)-N-[5-chloro-2-(1H-tetrazol-5-yl)-phenyl]-3-(4-fluoro-3-trifluoromethyl-phenyl)-acrylamide 
• 1034331-08-2 (E)-N-[5-chloro-2-(1H-tetrazol-5-yl)-phenyl]-3-naphthalen-2-yl-acrylamide 
• 1034331-13-9 (E)-N-[5-chloro-2-(1H-tetrazol-5-yl)-phenyl]-3-(3,4-dichloro-phenyl)-acrylamide 

Relevant articles and documents

Azosemide intermediate synthesizing method

The invention discloses an azosemide intermediate synthesizing method. The method comprises the steps of performing tetrazole reaction to prepare a compound A: warming and enabling 4-chlorin-2-nitro benzonitrile and sodium azide to react under action of a catalyst and extracting reaction liquid by water to obtain reaction liquid of the compound A; directly performing hydrogenation reaction to prepare a compound B; performing chlorosulfonation reaction to prepare a compound C: slowly dropping qualified compound B and chlorosulfonic acid into cold water after temperature reaction and center control qualification, extracting through an organic solvent, standing for layering and decompressing, evaporating and drying the solvent in an organic phase mode to obtain a compound crude product C; performing ammonolysis reaction to prepare a compound D. Compared with the prior art, raw materials of the method disclosed by the invention are easy to obtain and low in cost; the method is low in cost, convenient to operate, suitable for industrialization and little in generated three wastes; furthermore, comprehensive utilization of waste can meet national industrial policy.

Synthesis of diverse azolo[c]quinazolines by palladium(II)- catalyzed aerobic oxidative insertion of isocyanides

We report the palladium(II)-catalyzed aerobic oxidative coupling of isocyanides with various (2-aminophenyl)azoles using air as the stoichiometric oxidant. A diverse range of medicinally valuable azolo[c]quinazolines was obtained by this new approach.

Bioisosteric modifications of 2-arylureidobenzoic acids: Selective noncompetitive antagonists for the homomeric kainate receptor subtype GluR5

2-Arylureidobenzoic acids (AUBAs) have recently been presented as the first series of selective noncompetitive GluR5 antagonists. In this paper we have modified the acidic moiety of the AUBAs by introducing different acidic and neutral groups, and similarly, we have replaced the urea linker of the AUBAs with other structurally related linkers. Replacing the acid with neutral substituents led to inactive compounds in all instances, showing that an acidic moiety is necessary for activity. Replacing the carboxylic moiety in 2a with a sulfonic acid (5c) or a tetrazole ring (5d) improved the potency at GluR5 receptors (compounds 5c and 5d showed IC50 values of 1.5 and 2.0 μM, respectively, compared to compound 2a with IC50 = 4.8 μM). Compound 5c did not show improved in vivo activity in the ATPA rigidity test compared to 2a, whereas compound 5d was 4 times more potent than 2a. All compounds wherein the urea linker had been replaced showed lower or no activity. The results described extend the knowledge of structure-activity relationships for the AUBAs, and compound 5d may prove to be a good candidate for studying GluR5 receptors in vitro and in vivo.